Skip to main content
. 2014 Sep 30;9(9):e106842. doi: 10.1371/journal.pone.0106842

Figure 8. Rescue of TGF-beta-downregulated TMEM16A expression by a Smad3 inhibitor (SIS3) and CFTR expression by a p38 MAPK inhibitor (SB203580).

Figure 8

T84 cells and HAECs were treated with either TGF-beta and SIS3 (5 µM, A and C) or TGF-beta and SB203580 (10 µM, B and D) for 48 h prior to lysis and immunoblot for TMEM16A (A and C) or CFTR (B and D). For each cell type, the upper gel panels show TMEM16A (A and C) or CFTR (B and D) detection from three replicate samples (with TGF-beta and either SIS3 or SB203580). SIS3 increased TMEM16A expression and SB203850 increased CFTR expression from TGF-beta-treated T84 cells and HAECs. The lower panels are summary densitometry data. T84 cells: *P<0.0002 for TMEM16A and CFTR control vs TGF-beta. **P<0.0007 for CFTR and TMEM16A + SB203580 and TGF-beta vs TGF-beta alone. HAECs: *P<0.035 for TMEM16A and CFTR control vs TGF-beta. **P<0.05 for CFTR and TMEM16A + SB203580 and TGF-beta vs TGF-beta alone.